Prostemics Co. Ltd
Ark Solutions Inc. engages in the research and development of products using protein in South Korea, Japan, Mexico, and internationally. It operates through Life and Health Business and Exosome Business divisions. The company offers products using stem cells. The company also provides cosmetics for hospitals and clinics, such as AAPE, a products containing high concentration human cell culture me… Read more
Prostemics Co. Ltd (203690) - Total Liabilities
Latest total liabilities as of September 2024: ₩33.62 Billion KRW
Based on the latest financial reports, Prostemics Co. Ltd (203690) has total liabilities worth ₩33.62 Billion KRW as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Prostemics Co. Ltd - Total Liabilities Trend (2015–2023)
This chart illustrates how Prostemics Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Prostemics Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Prostemics Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tristar Gold
OTCQB:TSGZF
|
USA | $2.60 Million |
|
Jaanh CosmeticsInc.
KQ:219550
|
Korea | ₩17.22 Billion |
|
Ray Co. Ltd
KQ:228670
|
Korea | ₩122.77 Billion |
|
Jagsonpal Pharmaceuticals Limited
NSE:JAGSNPHARM
|
India | ₹461.88 Million |
|
CHA Vaccine Institute Co. Ltd.
KQ:261780
|
Korea | ₩22.26 Billion |
|
Intchains Group Limited American Depositary Shares
NASDAQ:ICG
|
USA | $40.13 Million |
|
Singapore Shipping Corporation Limited
F:W1M
|
Germany | €60.81 Million |
Liability Composition Analysis (2015–2023)
This chart breaks down Prostemics Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prostemics Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prostemics Co. Ltd (2015–2023)
The table below shows the annual total liabilities of Prostemics Co. Ltd from 2015 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | ₩46.76 Billion | +12.25% |
| 2022-12-31 | ₩41.65 Billion | +6.17% |
| 2021-12-31 | ₩39.23 Billion | +1.37% |
| 2020-12-31 | ₩38.70 Billion | +1010.42% |
| 2019-12-31 | ₩3.49 Billion | +144.64% |
| 2018-12-31 | ₩1.42 Billion | -0.11% |
| 2017-12-31 | ₩1.43 Billion | -35.29% |
| 2016-12-31 | ₩2.20 Billion | -43.58% |
| 2015-12-31 | ₩3.91 Billion | -- |